PreciseDx
New York
About PreciseDx
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient. Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $42.7M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2025)
- Website: precisedx.ai
- Phone: 646-818-9330
Industries & Categories
Health Care
Social Profiles
Canonical: https://fsome.com/organization/precisedx-78718 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.